Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

Bromodomain and extra terminal domain (BET) proteins are important epigenetic regulators facilitating the transcription of genes in chromatin areas linked to acetylated histones. JQ1, a BET protein inhibitor, has antiproliferative activity against many cancers, mainly through inhibition of c‐MYC and upregulation of p21. In this research, we investigated the use of JQ1 for human osteosarcoma (OS) treatment. JQ1 significantly inhibited the proliferation and survival of OS cells inducing G1 cell cycle arrest, premature senescence, but little effect on apoptosis. Interestingly, c‐MYC protein levels in JQ1‐treated cells remained unchanged, whereas the upregulation of p21 protein was still observable. Although effective in vitro, JQ1 alone failed to reduce the size of the MNNG/HOS xenografts in immunocompromised mice. To overcome the resistance of OS cells to JQ1 treatment, we combined JQ1 with rapamycin, an mammalian target of rapamycin (mTOR) inhibitor. JQ1 and rapamycin synergistically inhibited the growth and survival of OS cells in vitro and in vivo. We also identified that RUNX2 is a direct target of bromodomain‐containing protein 4 (BRD4) inhibition by JQ1 in OS cells. Chromatin immunoprecipitation (ChIP) showed that enrichment of BRD4 protein around RUNX2 transcription start sites diminished with JQ1 treatment in MNNG/HOS cells. Overexpression of RUNX2 protected JQ1‐sensitive OS cells from the effect of JQ1, and siRNA‐mediated inhibition of RUNX2 sensitized the same cells to JQ1. In conclusion, our findings suggest that JQ1, in combination with rapamycin, is an effective chemotherapeutic option for OS treatment. We also show that inhibition of RUNX2 expression by JQ1 partly explains the antiproliferative activity of JQ1 in OS cells.

[1]  J. Bradner,et al.  Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle , 2014, Nature Communications.

[2]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[3]  S. Ogawa,et al.  Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival , 2013, Oncogenesis.

[4]  G. Stein,et al.  The cancer‐related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines , 2013, Journal of cellular physiology.

[5]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[6]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[7]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[8]  Alberto Del Rio,et al.  Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives , 2012, Current pharmaceutical design.

[9]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[10]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[11]  J. Squire,et al.  The Genetics of Osteosarcoma , 2012, Sarcoma.

[12]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[13]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[14]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[15]  J. Said,et al.  Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. , 2011, Cancer letters.

[16]  G. Stein,et al.  The Role of RUNX2 in Osteosarcoma Oncogenesis , 2010, Sarcoma.

[17]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[18]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[19]  Z. Lou,et al.  A c-Myc–SIRT1 feedback loop regulates cell growth and transformation , 2009, The Journal of cell biology.

[20]  Qiang Zhou,et al.  Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.

[21]  G. Braunstein,et al.  Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo , 2006, Clinical Cancer Research.

[22]  P. M. Nissom,et al.  A novel normalization method for effective removal of systematic variation in microarray data , 2006, Nucleic acids research.

[23]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Paul T. Groth,et al.  The ENCODE (ENCyclopedia Of DNA Elements) Project , 2004, Science.

[25]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[26]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[27]  S. K. Zaidi,et al.  Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter , 2002, Molecular and Cellular Biology.

[28]  K. Miyazono,et al.  A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Mock,et al.  c-myc amplification and expression in newly established human osteosarcoma cell lines. , 1987, Cancer research.

[30]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[31]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.